Dr. Nader H. Moniri
Associate Dean for Research and Professor of Pharmaceutical Sciences
- B.S., Biological Sciences, Georgia State University
- Ph.D., Pharmaceutical Sciences, University of North Carolina at Chapel Hill
- Postdoctoral Fellow, Pharmacology, Duke University Medical Center
Research Background and Interests
Dr. Moniri’s training has focused on molecular pharmacology and signal transduction of G protein-coupled receptors (GPCR) as well as the design and development of novel agents which modulate GPCR function.
Current research interests include signal transduction, alternative signaling, and design of functionally selective modulators of the prototypical GPCR, the beta-2-adrenergic receptor. Specifically, this work seeks to characterize mechanisms of beta-2-adrenergic mediated generation of intracellular reactive oxygen species, formation of which we have recently shown to be indispensable for receptor function.
Dr. Moniri’s laboratory is also interested in characterization of neuro-endocrine GPCRs which are involved in glucagon/insulin homeostasis, food intake, and satiety, as well as development of novel anti-diabetic agents which target these GPCRs.
- PHA 450 Nervous System Disorders I
- PHA 451 Nervous System Disorders II
- PHA 533 Musculoskeletal Disorders
- PHA 534 Endocrine Disorders
- PHA 554 Infectious Diseases I
- PHA 555 Infectious Diseases II
- PHA 815 Methods in Cell and Molecular Biology
- PHA 899 Doctoral Research
- Rambacher KM and Moniri NH. Cysteine redox state regulates human β2-adrenergic receptor binding and function. Scientific Reports, 10:2934, 1-15, 2020.
- Senatorov IS, Cheshmehkani A, Burns RN, Singh, K, Moniri NH. Carboxy-terminal phosphoregulation of the long splice isoform of Free-Fatty Acid Receptor-4 mediates β-arrestin recruitment and signaling to ERK1/2. Mol. Pharmacol. 97:304-313, 2020.
- Moniri NH. Reintroduction of quazepam: an update on comparative hypnotic and adverse effects. Intl. Clin. Psychopharmacol. 34:275-285, 2019.
- Murnane KS, Guner OF, Bowen JP, Rambacher KM, Moniri NH, Murphy TJ, Daphney CM, Oppong-Damoah A, Rice KC. The adrenergic receptor antagonist carvedilol interacts with serotonin 2A receptors both in vitro and in vivo. Pharmacol Biochem Behav. 181:37-45, 2019.
- Moniri NH, Momary KM, McMahon TJ, Nayee E. Statin-associated Achilles tendon rupture and reproducible bilateral tendinopathy upon repeated exposure. Mayo Clin Proc. 93(10):1530-1532, 2018.
- Senatorov IS and Moniri NH. The role of free-fatty acid receptor-4 (FFA4) in human cancers and cancer cell lines. Biochem Pharmacol. 150:170-180, 2018.
- Cheshmehkani A, Senatorov IS, Dhuguru J, Ghoneim O, Moniri NH. Free-fatty acid receptor-4 (FFA4) modulates ROS generation and COX-2 expression via the C-terminal β-arrestin phosphosensor in Raw264.7 macrophages. Biochemical Pharmacol. 146:139-150, 2017.
- Moniri NH. Free-fatty acid receptor-4 (GPR120): cellular and molecular function and its role in metabolic disorders. Biochemical Pharmacol. 110-111:1-15, 2016.
- Cheshmehkani A, Senatorov IS, Kandi P, Singh M, Britt A, Hayslett R, Moniri NH. Fish oil and flax seed oil supplemented diets increase FFAR4 expression in the rat colon. Inflamm Res. 2015 Oct;64(10):809-15.
- Singh M and Moniri NH. Reactive oxygen species as ß2-adrenergic receptor signal transducers. J. Pharmaceu Pharmacol. 2(1): 8-15, 2014.
- Burns RN, Singh M, Senatorov IS, Moniri NH. Mechanisms of homologous and heterologous phosphorylation of FFA receptor 4 (GPR120): GRK6 and PKC mediate phosphorylation of Thr347, Ser350, and Ser357 in the C-terminal tail. Biochem Pharmacol, 87:650-659, 2014.
- Ryan GJ, Moniri NH., Smiley DD. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. Am J Health Syst Pharm, 70(13):1123-1131, 2013.
- Gleason BL, Siracuse MV, Moniri NH, Birnie CR, Okamoto CT, Crouch MA. Evolution of Preprofessional Pharmacy Curricula. Am J Pharm Educ. 77(5):95; 1-8, 2013.
- Singh M., and Moniri NH. Reactive oxygen species are required for ß2 adrenergic receptor-ß-arrestin interactions and signaling to ERK1/2. Biochem Pharmacol. 84(5):661-669, 2012.
- Burns RN and Moniri NH. Agonist- and H2O2- mediated oxidation of the ß2 adrenergic receptor: evidence of receptor S-sulfenation as detected by a modified biotin switch assay. J Pharmacol Exp Ther. 339(3):914-921, 2011.
- Wang Z, Humphrey C, Frilot N, Wang G., Nie Z, Moniri NH, Daaka Y. Dynamin2- and endothelial nitric oxide synthase-regulated invasion of bladder epithelial cells by uropathogenic Escherichia coli. J Cell Biol. 10;192(1):101-10, 2011.
- Burns RN and Moniri NH. Agonism with the omega-3 fatty acids alpha-linolenic acid and docosahexaenoic acid mediates phosphorylation of both the short and long isoforms of the human GPR120 receptor. Biochem Biophys Res Commun., 396: 1030-1035, 2010.
- Bagchi G, Wu J, French J, Kim J, Moniri NH, Daaka Y. Androgens transduce the G as-mediated activation of protein kinase A in prostate cells. Cancer Res., 68(9): 3225-31, 2008.
- Moniri NH. The Use of a Patient-based Medicinal Chemistry Case in the Nervous System I course. Let’s think about it! 11(2):1-3, Spring, 2008.
- Moniri NH and Daaka Y. Agonist-stimulated Reactive Oxygen Species Formation Regulates ß2-adrenergic Receptor Signal Transduction. Biochem Pharmacol., 74: 64-73, 2007.
- Booth RG and Moniri NH. Novel Ligands Stabilize Stereo-selective Conformations of the Histamine H1 Receptor to Activate Catecholamine Synthesis. Inflamm Res., 56:S1-2, 2007.
- Moniri NH and Booth RG. Role of PKA and PKC in Histamine H1 Receptor-mediated Activation of Catecholamine Neurotransmitter Synthesis. Neurosci Lett., 407:249-253, 2006.
- Bagchi G, Moniri NH, Daaka Y. Androgen Receptor. AfCS-Nature Molecules Pages, 2006.
- Guo R, Kasbohm EA, Arora P, Sample CJ, Baban B, Sud N, Sivashanmugam P, Moniri NH, Daaka Y. Expression and Function of Lysophosphatidic Acid LPA1 Receptor in Prostate Cancer Cells. Endocrinology, 147:4883-4892, 2006.
- Wang G, Moniri NH, Ozawa K, Stamler JS, Daaka Y. Nitric Oxide Regulates Endocytosis by S-nitrosylation of Dynamin. Proc Natl Acad Sci., USA, 103(5):1295-1300, 2006.
- Booth RG and Moniri NH. Ligand-directed multifunctional signaling of histamine H1 receptors. Inflamm Res, 54:S44-45, 2005.
- Moniri NH, Covington-Strachan DW, Booth RG. Ligand-directed functional heterogeneity of histamine H1 receptors: Novel agonists selectively activate and block H1 mediated phospholipase C and adenylyl cyclase signaling in CHO cells. J Pharmacol Exp Ther., 311:274-281, 2004.
- Moniri NH and Booth RG. Functional heterogeneity of histamine H1 receptors. Inflamm Res, 53:S71-72, 2004.
- Booth RG, Moniri NH, Bakker RA, Choksi NY, Nix WB, Timmerman H, Leurs R. A novel phenylaminotetralin radioligand reveals a sub-population of histamine H1 receptors. J Pharmacol Exp Ther., 302:328-336, 2002.
Contact Dr. Nader H. Moniri